BIOMAT Database Logo BIOMAT Database Logo

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) 1990

T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
University Hospital Nijmegen, The Netherlands.

This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who received an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the 2-year disease-free survival. Thirty-four patients received intensive chemotherapy prior to the conditioning for BMT. The 2-year disease-free survival was 60% for the 16 patients transplanted in complete remission. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (2-year disease-free survival: 18%) while none of those who either relapsed or were resistant to chemotherapy survived BMT for 2 years. Forty-four patients had not received any prior intensive chemotherapy. The disease-free survival at 2 years after BMT was 58 +/- 19% when a patient was transplanted for refractory anaemia (RA(S], 74 +/- 14% for refractory anaemia with excess of blasts (RAEB), 50 +/- 16% for RAEB in transformation (RAEBt), and 18 +/- 11% for secondary AML. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005260 Female Females

Related Publications

T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation.
June 1988, Lancet (London, England),
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome.
July 1990, British journal of haematology,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Allogeneic bone marrow transplantation in haematological malignancies. Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).
December 1989, Bone marrow transplantation,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).
June 1994, Leukemia,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
December 1996, British journal of haematology,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
May 1996, Bone marrow transplantation,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Allogeneic bone marrow transplantation for leukemia in Europe: regional differences. Report from the Leukemia Working party of the European Group for Bone Marrow Transplantation.
March 1990, Bone marrow transplantation,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
April 2000, Lancet (London, England),
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
November 1993, Blood,
T De Witte, and F Zwaan, and J Hermans, and J Vernant, and H Kolb, and J Vossen, and B Lönnqvist, and D Beelen, and A Ferrant, and J Gmür
Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group--Infectious Diseases Working Party.
November 1994, Bone marrow transplantation,
Copied contents to your clipboard!